Get the Stockscreener App
1.02
3.89%
+0.0382
After Hours:
1.02
Kronos Bio Inc stock is currently priced at $1.02, with a 24-hour trading volume of 249.63K.
It has seen a +3.89% increased in the last 24 hours and a -1.92% declined in the past month.
The chart indicates a potential bullish trend, as the stock is above the $0.9869 pivot point. If it approaches the $1.01 resistance level, significant changes may occur.
Previous Close:
$0.9818
Open:
$1
24h Volume:
249.63K
Market Cap:
$61.30M
Revenue:
-
Net Income/Loss:
$-112.67M
P/E Ratio:
-0.4834
EPS:
-2.11
Net Cash Flow:
$-79.26M
1W Performance:
+0.00%
1M Performance:
-1.92%
6M Performance:
-8.11%
1Y Performance:
-43.96%
1D Range:
$0.982
$1.04
52W Range:
$0.731
$2.29
Kronos Bio Inc Stock (KRON) Company Profile
Name
Kronos Bio Inc
Sector
Industry
Phone
650-781-5200
Address
1300 South El Camino Real, Suite 300, San Mateo
Kronos Bio Inc Stock (KRON) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-14-22 | Initiated | Berenberg | Buy |
| Oct-20-21 | Resumed | Cowen | Outperform |
| Jun-24-21 | Initiated | H.C. Wainwright | Buy |
| Nov-03-20 | Initiated | Cowen | Outperform |
| Nov-03-20 | Initiated | Goldman | Buy |
| Nov-03-20 | Initiated | Jefferies | Buy |
| Nov-03-20 | Initiated | Piper Sandler | Overweight |
View All
Kronos Bio Inc Stock (KRON) Latest News
Biopharma Layoff Tracker 2024: Erasca, Bolt, Tenaya and More Cut Staff - BioSpace
BioSpace
Biopharma Layoff Tracker 2024: Erasca, Bolt, Tenaya and More Cut Staff - BioSpace
BioSpace
Biopharma Layoff Tracker 2024: Erasca, Bolt, Tenaya and More Cut Staff - BioSpace
BioSpace
Biopharma Layoff Tracker 2024: Erasca, Bolt, Tenaya and More Cut Staff - BioSpace
BioSpace
Biopharma Layoff Tracker 2024: Erasca, Bolt, Tenaya and More Cut Staff - BioSpace
BioSpace
Down -5.63% in 4 Weeks, Here's Why Kronos Bio (KRON) Looks Ripe for a Turnaround - Yahoo Finance Australia
Yahoo Finance Australia
Kronos Bio Inc Stock (KRON) Financials Data
Kronos Bio Inc (KRON) Net Income 2024
KRON net income (TTM) was -$112.67 million for the quarter ending December 31, 2023, a +15.41% increase year-over-year.
Kronos Bio Inc (KRON) Cash Flow 2024
KRON recorded a free cash flow (TTM) of -$79.26 million for the quarter ending December 31, 2023, a +13.38% increase year-over-year.
Kronos Bio Inc (KRON) Earnings per Share 2024
KRON earnings per share (TTM) was -$1.95 for the quarter ending December 31, 2023, a +17.72% growth year-over-year.
About Kronos Bio Inc
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib, a selective inhibitor targeting spleen tyrosine kinase in acute myeloid leukemia patients. The company is also developing KB-0742, an orally bioavailable inhibitor of cyclin dependent kinase 9 for the treatment of MYC-amplified solid tumors. Kronos Bio, Inc. is founded in 2017 and is headquartered in San Mateo, California.
0.77%
1.20%
Cap:
|
Volume (24h):